Saniona AB (SANION) AI Stock Analysis

• Market Cap: kr2.16B
• Dividend Yield: N/A
• Average Volume (3M): 1.06M
• Price to Earnings (P/E): 9.6
• Beta (1Y): -0.33
• Revenue Growth: 2687.51%
• EPS Growth: N/A
• Country: SE
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 138,030,140
• 10 Day Avg. Volume: 913,988
• 30 Day Avg. Volume: 1,064,614
• PEG Ratio: 0.39
• Price to Book (P/B): 4.30
• Price to Sales (P/S): 6.29
• P/FCF Ratio: 13.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): kr11.00M

• Rating: 59 Neutral
• Price Target: kr15.00 ▼(-28.91% Downside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

The score is held back primarily by weak technicals (strong downtrend with negative momentum), partially offset by improved recent financial performance (profitability and cash flow turning positive, debt-free balance sheet) and an attractive P/E valuation.

Positive Factors

Improved Cash Generation

The firm delivered positive operating and free cash flow in 2024–2025 after years of burn, which materially improves sustainability. Durable cash generation reduces near-term financing dependency, supports R&D pacing and partnering negotiation leverage, and underpins multi‑quarter operational stability.

Debt‑Free Balance Sheet

Reporting zero total debt in 2025 materially lowers financial risk and interest burden, giving management flexibility to fund trials or structure partnerships. A conservative leverage profile supports long‑term resilience through R&D cycles and reduces the likelihood of distressed financings during development ramps.

Partnering‑Driven Model & Niche Focus

A partnering/licensing model with focus on ion‑channel small molecules lets the company de‑risk commercialization, monetize milestones and royalties, and conserve capital. The specialized ion‑channel expertise creates a durable technical differentiation that supports repeated collaboration opportunities with larger biopharma players.

Negative Factors

Revenue Volatility

Material swings in revenue across consecutive years indicate heavy reliance on lumpy milestone or licensing receipts. That uneven top‑line makes margins and cash generation difficult to predict, complicates multi‑quarter planning and raises the chance that profitability proves transitory without repeatable revenue streams.

Sharp FCF Decline in 2025

Although FCF turned positive overall, a 64.8% decline in a single year shows cash generation is sensitive to timing of partner payments and operating variability. This lumpy pattern can force more frequent external financings or delayed programs, undermining the apparent improvement in cash durability.

Small Scale Operations

A very small headcount constrains internal development bandwidth and increases dependence on external partners and CROs for trial execution. Limited scale raises execution risk for advancing multiple programs concurrently and can slow timelines, making long‑term pipeline delivery more contingent on partner support.

Saniona AB Business Overview & Revenue Model

Company Description

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

How the Company Makes Money

Saniona AB generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates in exchange for milestone payments and royalties on future sales. Additionally, the company may receive upfront payments as part of licensing agreements for its proprietary technologies and products. As Saniona progresses its candidates through clinical trials, it can also attract further investments and grants aimed at supporting its research and development efforts, contributing to its overall earnings potential.

Saniona AB Financial Statement Overview

Summary

Financials show a clear turnaround: strong net income and positive operating/free cash flow in 2024–2025, and a healthier 2025 balance sheet with zero debt. The main risk is volatility—revenue fell sharply in 2025 and free cash flow dropped materially year over year—so the recent strength appears less proven as durable.

Income Statement

Profitability improved sharply in 2024–2025, with the company delivering strong net income in both years after large losses in 2020–2023. Margins in 2024 were exceptionally high, supporting a strong earnings rebound. The key weakness is volatility and dependence on revenue that swung materially: revenue grew in 2024 (+18.9%) but fell significantly in 2025 (-41.6%), which raises concerns about the durability of recent profitability.

Balance Sheet

Leverage appears conservative in the most recent year, with zero total debt reported in 2025 and a sizeable equity base versus total assets. The balance sheet also improved meaningfully from 2023, when equity was negative and leverage metrics were strained. The main risk is historical instability in capital structure (negative equity in 2023 and higher debt in earlier years), which suggests the balance sheet has been improving but has not been consistently strong across the full period.

Cash Flow

Cash generation strengthened substantially in 2024–2025, with positive operating cash flow and positive free cash flow in both years, following several years of heavy cash burn (2020–2023). However, free cash flow fell sharply in 2025 (down 64.8% year over year), indicating cash generation can be volatile and may fluctuate with operating performance and timing effects.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	434.40M	334.67M	16.84M	15.28M	10.48M
Gross Profit	274.72M	329.58M	11.78M	10.81M	5.85M
EBITDA	281.45M	251.90M	-68.28M	-198.41M	-398.86M
Net Income	284.67M	188.71M	-95.81M	-245.36M	-410.90M
Balance Sheet
Total Assets	679.74M	339.73M	64.14M	153.70M	440.25M
Cash, Cash Equivalents and Short-Term Investments	580.82M	303.26M	30.96M	111.71M	356.86M
Total Debt	0.00	10.50M	71.41M	81.52M	99.77M
Total Liabilities	44.58M	107.92M	86.08M	100.99M	158.25M
Stockholders Equity	635.16M	231.82M	-21.94M	52.71M	282.00M
Cash Flow
Free Cash Flow	200.30M	249.07M	-85.66M	-282.52M	-346.52M
Operating Cash Flow	273.86M	249.20M	-85.53M	-281.54M	-345.04M
Investing Cash Flow	-77.62M	-124.00K	-129.00K	6.84M	43.16M
Financing Cash Flow	108.19M	23.25M	-7.97M	-20.52M	50.60M

Saniona AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 21.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Neutral. The current price of 21.1 is above the 20-day moving average (MA) of 20.75, below the 50-day MA of 22.47, and above the 200-day MA of 15.11, indicating a neutral trend. The MACD of -2.51 indicates Positive momentum. The RSI at 31.67 is Neutral, neither overbought nor oversold. The STOCH value of 11.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SANION.

Saniona AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	59 Neutral	kr2.16B	9.60	167.77%	―	2687.51%	―
SYNACT	56 Neutral	kr981.28M	-10.42	-58.41%	―	―	48.14%
CANTA	55 Neutral	€1.02B	7.07	81.19%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCO	49 Neutral	kr612.03M	-4.37	―	―	131.20%	32.28%
XBRANE	46 Neutral	kr123.63M	121.99	-16.90%	―	4.64%	―
XSPRAY	44 Neutral	kr1.02B	-7.05	-35.03%	―	―	25.14%

Saniona AB Corporate Events

Saniona Shifts From Partnership-Driven Gains to Clinical Execution in 2025

Saniona reported full-year 2025 revenue of SEK 434.4 million, up from SEK 334.7 million, with operating profit rising to SEK 271.0 million and net profit to SEK 284.6 million, supported by a solid cash position of SEK 580.8 million. However, the fourth quarter showed a sharp revenue drop to SEK 4.6 million and an operating loss of SEK 46.5 million, as the company invests in moving multiple proprietary programs toward the clinic.

The company underscored a strategic shift from partnership validation to disciplined clinical execution, signaling a focus on translating its ion channel expertise into late-stage assets and long-term value creation. New leadership appointments in clinical development, translational medicine, toxicology and CMC are intended to reinforce operational capabilities, positioning Saniona for the next phase of growth and execution for both patients and shareholders.

The most recent analyst rating on (SE:SANION) stock is a Buy with a SEK30.00 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.

Saniona Sets February Investor Call to Present Q4 Results and Pipeline Update

Saniona AB, a Copenhagen-based clinical-stage biopharmaceutical company listed on the Nasdaq Stockholm Main Market, develops treatments for neurological and psychiatric disorders, including pipeline assets for paediatric epilepsy, epilepsy, and major depressive disorder. The company advances its portfolio through internal R&D, strategic licensing deals for epilepsy, essential tremor, and obesity therapies, and partnership-ready programs in rare eating disorders and inflammatory bowel disease.

Saniona announced it will host its Q4 and year-end investor call on 26 February 2026 at 11:00 CET, where management will present financial results and provide a broader company update. The event, which includes an online Q&A session and replay access via webcast, offers investors and stakeholders a key opportunity to gauge recent operational progress and the status of its partnered and proprietary clinical programs, potentially informing sentiment around the company’s strategic trajectory and pipeline execution.

The most recent analyst rating on (SE:SANION) stock is a Buy with a SEK30.00 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.

Saniona Strengthens Leadership to Advance CNS Programs

Saniona AB has announced new leadership appointments to enhance its clinical development, translational medicine, toxicology, and CMC capabilities, aiming to accelerate the advancement of its CNS pipeline. These strategic appointments are expected to improve operational efficiency and support the company’s CNS programs, which include SAN2219, SAN2465, and SAN2668, as they approach critical clinical and regulatory milestones. The enhanced leadership team is anticipated to drive the company’s growth and increase the probability of success in delivering meaningful clinical results, ultimately creating long-term shareholder value.

The most recent analyst rating on (SE:SANION) stock is a Buy with a SEK20.00 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.